Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood markers could spot sepsis in newborns faster

NCT ID NCT07635264

Diagnosis Sponsor: Mersin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining standard blood markers (like CRP and PCT) with newer ones (like immature granulocytes and platelet ratios) could more accurately diagnose late-onset sepsis in full-term newborns. Researchers reviewed data from 128 babies to see how well these tests worked over time. The goal is to help doctors diagnose serious infections faster and more reliably.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

128 people

The number who actually took part.

Started

Jul 2020

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study was conducted with two groups: term patients (38-42 weeks' gestation) and controls. The control group was selected to match the sepsis group as closely as possible (at a 1:1 ratio) in terms of demographic characteristics, and taking gestational age into account

Ages

3 to 28 days

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Term newborn * Late-onset neonatal sepsis Exclusion Criteria: * Preterm newborn * Major congenital anomaly * Congenital metabolic disease * Hemolytic anemia * Hematological diseases * Congenital leukemia * Dyserythropoietic anemia * Early-onset neonatal sepsis Control group * Neonatal jaundice (indirect hyperbilirubinemia) * Transient neonatal tachypnea * Early neonatal sepsis Exclusion criteria Perinatal asphyxia, Meconium aspiration syndrome Polycythemia İntraventricular hemoragy Pneumothorax Hemolytic Anemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation indices are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neonatal Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation indices Late onset neonatal sepsis

Contacts and locations

Locations

  • Mersin University

    Mersin, 33310, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.